These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 21541038)

  • 21. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
    Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
    Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Integrative prediction of gene function and platinum-free survival from genomic and epigenetic features in ovarian cancer.
    Wrzeszczynski KO; Varadan V; Kamalakaran S; Levine DA; Dimitrova N; Lucito R
    Methods Mol Biol; 2013; 1049():35-51. PubMed ID: 23913207
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epigenetic disruption of miR-130a promotes prostate cancer by targeting SEC23B and DEPDC1.
    Ramalho-Carvalho J; Martins JB; Cekaite L; Sveen A; Torres-Ferreira J; Graça I; Costa-Pinheiro P; Eilertsen IA; Antunes L; Oliveira J; Lothe RA; Henrique R; Jerónimo C
    Cancer Lett; 2017 Jan; 385():150-159. PubMed ID: 27984115
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells.
    Baba T; Convery PA; Matsumura N; Whitaker RS; Kondoh E; Perry T; Huang Z; Bentley RC; Mori S; Fujii S; Marks JR; Berchuck A; Murphy SK
    Oncogene; 2009 Jan; 28(2):209-18. PubMed ID: 18836486
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epigenetic mechanisms and therapeutic targets of chemotherapy resistance in epithelial ovarian cancer.
    Borley J; Brown R
    Ann Med; 2015; 47(5):359-69. PubMed ID: 26158617
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transcriptional epigenetic regulation of Fkbp1/Pax9 genes is associated with impaired sensitivity to platinum treatment in ovarian cancer.
    Soto JA; Rodríguez-Antolín C; Vera O; Pernía O; Esteban-Rodríguez I; Dolores Diestro M; Benitez J; Sánchez-Cabo F; Alvarez R; De Castro J; Ibanez de Cáceres I
    Clin Epigenetics; 2021 Aug; 13(1):167. PubMed ID: 34454589
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epigenetics in ovarian cancer: premise, properties, and perspectives.
    Yang Q; Yang Y; Zhou N; Tang K; Lau WB; Lau B; Wang W; Xu L; Yang Z; Huang S; Wang X; Yi T; Zhao X; Wei Y; Wang H; Zhao L; Zhou S
    Mol Cancer; 2018 Jul; 17(1):109. PubMed ID: 30064416
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The significance of epigenetic alterations in lung carcinogenesis.
    Brzeziańska E; Dutkowska A; Antczak A
    Mol Biol Rep; 2013 Jan; 40(1):309-25. PubMed ID: 23086271
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epigenetic activation of POTE genes in ovarian cancer.
    Sharma A; Albahrani M; Zhang W; Kufel CN; James SR; Odunsi K; Klinkebiel D; Karpf AR
    Epigenetics; 2019 Feb; 14(2):185-197. PubMed ID: 30764732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multivalent epigenetic marks confer microenvironment-responsive epigenetic plasticity to ovarian cancer cells.
    Bapat SA; Jin V; Berry N; Balch C; Sharma N; Kurrey N; Zhang S; Fang F; Lan X; Li M; Kennedy B; Bigsby RM; Huang TH; Nephew KP
    Epigenetics; 2010; 5(8):716-29. PubMed ID: 20676026
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells.
    Abbosh PH; Montgomery JS; Starkey JA; Novotny M; Zuhowski EG; Egorin MJ; Moseman AP; Golas A; Brannon KM; Balch C; Huang TH; Nephew KP
    Cancer Res; 2006 Jun; 66(11):5582-91. PubMed ID: 16740693
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aberrant TGFβ/SMAD4 signaling contributes to epigenetic silencing of a putative tumor suppressor, RunX1T1 in ovarian cancer.
    Yeh KT; Chen TH; Yang HW; Chou JL; Chen LY; Yeh CM; Chen YH; Lin RI; Su HY; Chen GC; Deatherage DE; Huang YW; Yan PS; Lin HJ; Nephew KP; Huang TH; Lai HC; Chan MW
    Epigenetics; 2011 Jun; 6(6):727-39. PubMed ID: 21540640
    [TBL] [Abstract][Full Text] [Related]  

  • 33. E2F6 functions as a competing endogenous RNA, and transcriptional repressor, to promote ovarian cancer stemness.
    Cheng FHC; Lin HY; Hwang TW; Chen YC; Huang RL; Chang CB; Yang W; Lin RI; Lin CW; Chen GCW; Mai SY; Lin JMJ; Chuang YM; Chou JL; Kuo LW; Li C; Cheng ASL; Lai HC; Wu SF; Tsai JC; Chan MWY
    Cancer Sci; 2019 Mar; 110(3):1085-1095. PubMed ID: 30582655
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epigenetics in ovarian cancer.
    Natanzon Y; Goode EL; Cunningham JM
    Semin Cancer Biol; 2018 Aug; 51():160-169. PubMed ID: 28782606
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Emerging Roles and Therapeutic Implications of Epigenetic Modifications in Ovarian Cancer.
    Wang Y; Huang Z; Li B; Liu L; Huang C
    Front Endocrinol (Lausanne); 2022; 13():863541. PubMed ID: 35620395
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of Epigenetic Drug Targeting of Heterogenous Tumor Cell Fractions Using Potential Biomarkers of Response in Ovarian Cancer.
    Singh AK; Chandra N; Bapat SA
    Clin Cancer Res; 2015 Nov; 21(22):5151-63. PubMed ID: 26130461
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MicroRNA Methylation in Colorectal Cancer.
    Kaur S; Lotsari-Salomaa JE; Seppänen-Kaijansinkko R; Peltomäki P
    Adv Exp Med Biol; 2016; 937():109-22. PubMed ID: 27573897
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MicroRNAs in ovarian carcinomas.
    Dahiya N; Morin PJ
    Endocr Relat Cancer; 2010 Mar; 17(1):F77-89. PubMed ID: 19903743
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overexpression of mucin 13 due to promoter methylation promotes aggressive behavior in ovarian cancer cells.
    Sung HY; Park AK; Ju W; Ahn JH
    Yonsei Med J; 2014 Sep; 55(5):1206-13. PubMed ID: 25048476
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MicroRNA signatures in human ovarian cancer.
    Iorio MV; Visone R; Di Leva G; Donati V; Petrocca F; Casalini P; Taccioli C; Volinia S; Liu CG; Alder H; Calin GA; Ménard S; Croce CM
    Cancer Res; 2007 Sep; 67(18):8699-707. PubMed ID: 17875710
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.